Vertex Pharmaceuticals Inc insider trading
VRTXfinancial statementsForm 4 filings on EDGAR306 transactions since Nov 1, 2024
From August 4, 2026 to November 1, 2026, 0 insiders at Vertex Pharmaceuticals Inc bought $0 of stock in the open market, and 0 sold $0. Officers and directors accounted for $0 of purchases and $0 of sales. The last reported transaction was an award by Brennan Daniel J. on October 20, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 22, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $0Aug 4, 2026 – Nov 1, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Oct 30, 2026. Insider data through Nov 1, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
306 transactions from November 1, 2024 to November 1, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 20, 2026 | Brennan Daniel J. | Director | award | 795 | $503.47 | $400K | 795 | Oct 22, 2026 |
| Sep 8, 2026 | van Grunsven Jasper | EVP, CP and NPPO | award | 8,682 | $0.00 | — | 8,682 | Sep 10, 2026 |
| Aug 28, 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | award | 5,000 | $0.00 | — | 11,624 | Sep 1, 2026 |
| Aug 27, 2026 | Sachs Bruce I | Director | gift | 6,000 | $0.00 | — | 39,000 | Aug 31, 2026 |
| Jul 21, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | award | 8,251 | $0.00 | — | 53,572 | Jul 23, 2026 |
| Jul 21, 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | award | 8,251 | $0.00 | — | 66,512 | Jul 23, 2026 |
| Jul 2, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | open-market sale10b5-1 | 1,500 | $524.99 | $787K | 45,321 | Jul 7, 2026 |
| Jul 2, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | open-market sale10b5-1 | 1,541 | $519.00 | $800K | 11,001 | Jul 7, 2026 |
| Jul 1, 2026 | Liu Joy | EVP and Chief Legal Officer | open-market sale10b5-1 | 828 | $502.71 | $416K | 19,131 | Jul 6, 2026 |
| Jun 26, 2026 | Bozic Carmen | EVP and CMO | open-market sale10b5-1 | 596 | $482.50 | $288K | 15,337 | Jun 30, 2026 |
| Jun 18, 2026 | Bozic Carmen | EVP and CMO | open-market sale10b5-1 | 1,020 | $462.17 | $471K | 15,933 | Jun 23, 2026 |
| Jun 15, 2026 | Bozic Carmen | EVP and CMO | open-market sale10b5-1 | 4,062 | $450.00 | $2M | 16,953 | Jun 17, 2026 |
| Jun 5, 2026 | Bozic Carmen | EVP and CMO | open-market sale10b5-1 | 1,745 | $450.00 | $785K | 21,015 | Jun 9, 2026 |
| Jun 1, 2026 | Liu Joy | EVP and Chief Legal Officer | open-market sale10b5-1 | 828 | $439.91 | $364K | 19,959 | Jun 3, 2026 |
| May 29, 2026 | Bozic Carmen | EVP and CMO | open-market sale10b5-1 | 1,974 | $450.00 | $888K | 22,760 | Jun 2, 2026 |
| May 15, 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | open-market sale10b5-1 | 33 | $453.45 | $15K | 7,284 | May 19, 2026 |
| May 15, 2026 | Bozic Carmen | EVP and CMO | open-market sale10b5-1 | 1,354 | $453.45 | $614K | 24,734 | May 19, 2026 |
| May 12, 2026 | Bozic Carmen | EVP and CMO | open-market sale10b5-1 | 6,988 | $450.00 | $3M | 26,088 | May 14, 2026 |
| May 4, 2026 | Bhatia Sangeeta N. | Director | open-market sale10b5-1 | 318 | $423.73 | $135K | 4,924 | May 5, 2026 |
| May 1, 2026 | Upadhyay Suketu | Director | disposition to issuer | 796 | — | — | 1,558 | May 5, 2026 |
| May 1, 2026 | Thornberry Nancy | Director | award | 472 | $0.00 | — | 2,507 | May 5, 2026 |
| May 1, 2026 | Thornberry Nancy | Director | disposition to issuer | 398 | — | — | 2,109 | May 5, 2026 |
| May 1, 2026 | Schneider Jennifer | Director | award | 472 | $0.00 | — | 2,190 | May 5, 2026 |
| May 1, 2026 | Schneider Jennifer | Director | disposition to issuer | 796 | — | — | 1,394 | May 5, 2026 |
| May 1, 2026 | Mckenzie Diana | Director | award | 943 | $0.00 | — | 3,174 | May 5, 2026 |
| May 1, 2026 | Mckenzie Diana | Director | disposition to issuer | 796 | — | — | 2,378 | May 5, 2026 |
| May 1, 2026 | Liu Joy | EVP and Chief Legal Officer | open-market sale10b5-1 | 1,104 | $425.02 | $469K | 20,729 | May 5, 2026 |
| May 1, 2026 | Garber Alan M | Director | award | 472 | $0.00 | — | 7,344 | May 5, 2026 |
| May 1, 2026 | Bhatia Sangeeta N. | Director | award | 943 | $0.00 | — | 5,242 | May 5, 2026 |
| Apr 1, 2026 | Liu Joy | EVP and Chief Legal Officer | open-market sale10b5-1 | 978 | $449.17 | $439K | 21,833 | Apr 3, 2026 |
| Mar 27, 2026 | Bozic Carmen | EVP and CMO | open-market sale10b5-1 | 2,329 | $450.95 | $1M | 33,076 | Mar 31, 2026 |
| Mar 13, 2026 | Bozic Carmen | EVP and CMO | open-market sale10b5-1 | 2,329 | $481.79 | $1M | 35,405 | Mar 17, 2026 |
| Mar 11, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | open-market sale10b5-1 | 2,633 | $498.42 | $1M | 12,489 | Mar 13, 2026 |
| Mar 4, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | open-market sale10b5-1 | 2,437 | $475.30 | $1M | 15,122 | Mar 6, 2026 |
| Mar 2, 2026 | Liu Joy | EVP and Chief Legal Officer | open-market sale10b5-1 | 892 | $495.96 | $442K | 22,811 | Mar 4, 2026 |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President, Director | open-market sale10b5-1 | 3,278 | $488.27 | $2M | 131,730 | Mar 3, 2026 |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President, Director | open-market sale10b5-1 | 2,510 | $487.13 | $1M | 135,008 | Mar 3, 2026 |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President, Director | open-market sale10b5-1 | 240 | $482.84 | $116K | 137,518 | Mar 3, 2026 |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President, Director | open-market sale10b5-1 | 120 | $481.50 | $58K | 137,758 | Mar 3, 2026 |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President, Director | open-market sale10b5-1 | 400 | $479.75 | $192K | 137,878 | Mar 3, 2026 |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President, Director | open-market sale10b5-1 | 460 | $489.32 | $225K | 131,270 | Mar 3, 2026 |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President, Director | open-market sale10b5-1 | 1,725 | $496.95 | $857K | 98,278 | Mar 3, 2026 |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President, Director | open-market sale10b5-1 | 5,995 | $496.16 | $3M | 100,003 | Mar 3, 2026 |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President, Director | open-market sale10b5-1 | 2,725 | $490.54 | $1M | 128,545 | Mar 3, 2026 |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President, Director | open-market sale10b5-1 | 949 | $491.30 | $466K | 127,596 | Mar 3, 2026 |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President, Director | open-market sale10b5-1 | 2,520 | $493.29 | $1M | 125,076 | Mar 3, 2026 |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President, Director | open-market sale10b5-1 | 3,498 | $494.33 | $2M | 121,578 | Mar 3, 2026 |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President, Director | open-market sale10b5-1 | 15,580 | $495.38 | $8M | 105,998 | Mar 3, 2026 |
| Feb 27, 2026 | Bozic Carmen | EVP and CMO | open-market sale10b5-1 | 2,329 | $480.31 | $1M | 37,734 | Mar 3, 2026 |
| Feb 26, 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | open-market sale10b5-1 | 357 | $483.36 | $173K | 6,624 | Mar 2, 2026 |
Who the insiders are
Everyone who reported a transaction since November 1, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Leiden Jeffrey M | Executive Chairman, Director | Feb 24, 2026 | tax withholding | 34,797 | — | $61M (17) | 17 of 17 |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | Jul 21, 2026 | award | 66,512 | — | $28M (9) | 9 of 9 |
| Kewalramani Reshma | CEO & President, Director | Feb 27, 2026 | open-market sale | 131,730 | — | $20M (13) | 13 of 13 |
| Bozic Carmen | EVP and CMO | Jun 26, 2026 | open-market sale | 15,337 | — | $11M (10) | 10 of 10 |
| Wagner Charles F JR | EVP, CO & FO | Feb 24, 2026 | tax withholding | 47,042 | — | $11M (3) | 3 of 3 |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Jul 21, 2026 | award | 53,572 | — | $7M (8) | 8 of 8 |
| McKechnie Duncan | EVP, Chief Commercial Officer | Jul 2, 2026 | open-market sale | 11,001 | — | $6M (5) | 5 of 5 |
| Biller Jonathan | EVP and Chief Legal Officer | Feb 25, 2026 | open-market sale | 13,659 | — | $4M (6) | 6 of 6 |
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Feb 25, 2026 | open-market sale | 18,432 | — | $4M (5) | 5 of 5 |
| Bunnage Mark E. | EVP, Chief Scientific Officer | May 15, 2026 | open-market sale | 7,284 | — | $3M (5) | 5 of 5 |
| Liu Joy | EVP and Chief Legal Officer | Jul 1, 2026 | open-market sale | 19,131 | — | $2M (5) | 5 of 5 |
| Ambrose Kristen | SVP & Chief Accounting Officer | Aug 28, 2026 | award | 11,624 | — | $2M (5) | 5 of 5 |
| Bhatia Sangeeta N. | Director | May 4, 2026 | open-market sale | 4,924 | — | $268K (2) | 2 of 2 |
| Altshuler David | EVP, Chief Scientific Officer | Jan 22, 2026 | award | 31,149 | — | — | — |
| Arbuckle Stuart A | EVP, COO | Jul 1, 2025 | tax withholding | 63,368 | — | — | — |
| Mckenzie Diana | Director | May 1, 2026 | award | 3,174 | — | — | — |
| Sachs Bruce I | Director | Aug 27, 2026 | gift | 39,000 | — | — | — |
| Upadhyay Suketu | Director | May 1, 2026 | disposition to issuer | 1,558 | — | — | — |
| Thornberry Nancy | Director | May 1, 2026 | award | 2,507 | — | — | — |
| Schneider Jennifer | Director | May 1, 2026 | award | 2,190 | — | — | — |
| Garber Alan M | Director | May 1, 2026 | award | 7,344 | — | — | — |
| Carney Lloyd | Director | Nov 19, 2025 | gift | 6,315 | — | — | — |
| Brennan Daniel J. | Director | Oct 20, 2026 | award | 795 | — | — | — |
| van Grunsven Jasper | EVP, CP and NPPO | Sep 8, 2026 | award | 8,682 | — | — | — |
Questions
Are Vertex Pharmaceuticals Inc insiders buying or selling?
Over the twelve months to November 1, 2026, 13 insiders at Vertex Pharmaceuticals Inc sold $158M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $158M. Only open-market purchases and sales are counted.
Who sold the most Vertex Pharmaceuticals Inc stock in the last year?
Leiden Jeffrey M (Executive Chairman, Director) sold $61M in 17 open-market sales over the twelve months to November 1, 2026.
Do Vertex Pharmaceuticals Inc executives sell under 10b5-1 plans?
93 of the 93 open-market sales in the last twelve months (100%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Vertex Pharmaceuticals Inc
- Vertex Pharmaceuticals Inc financial statements
- 1 tracked fund holding VRTX
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.